Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Aspirin for the prevention of recurrent venous thromboembolism: The INSPIRE Collaboration

Simes, John, Becattini, Cecilia, Agnelli, Giancarlo, Eikelboom, John W., Kirby, Adrienne C., Mister, Rebecca, Prandoni, Paolo, Brighton, Timothy A. and Baker, R.I. (2014) Aspirin for the prevention of recurrent venous thromboembolism: The INSPIRE Collaboration. Circulation, 130 (13). pp. 1062-1071.

Link to Published Version:
*Subscription may be required


Background—In patients with a first unprovoked venous thromboembolism (VTE) the risk of recurrent VTE remains high after anticoagulant treatment is discontinued. The Aspirin for the Prevention of Recurrent Venous Thromboembolism (the Warfarin and Aspirin [WARFASA]) and the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trials showed that aspirin reduces this risk, but they were not individually powered to detect treatment effects for particular outcomes or subgroups.

Methods and Results—An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups. The primary analysis, for VTE, was by intention to treat using time-to-event data. Of 1224 patients, 193 had recurrent VTE over 30.4 months’ median follow-up. Aspirin reduced recurrent VTE (7.5%/yr versus 5.1%/yr; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.51–0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47–0.92; P=0.01) and pulmonary embolism (HR, 0.66; 95% CI, 0.41–1.06; P=0.08). Aspirin reduced major vascular events (8.7%/yr versus 5.7%/yr; HR, 0.66; 95% CI, 0.50–0.86; P=0.002). The major bleeding rate was low (0.4%/yr for placebo and 0.5%/yr for aspirin). After adjustment for treatment adherence, recurrent VTE was reduced by 42% (HR, 0.58; 95% CI, 0.40–0.85; P=0.005). Prespecified subgroup analyses indicate similar relative, but larger absolute, risk reductions in men and older patients.

Conclusions—Aspirin after anticoagulant treatment reduces the overall risk of recurrence by more than a third in a broad cross-section of patients with a first unprovoked VTE, without significantly increasing the risk of bleeding.

Item Type: Journal Article
Murdoch Affiliation(s): Institute for Immunology and Infectious Diseases
Publisher: American Heart Foundation
Copyright: © 2014 American Heart Association, Inc.
Other Information: Ross baker appears courtesy of the INSPIRE study Investigators
Item Control Page Item Control Page